Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety Extension Study to Evaluate the Biodegradation of the Brimonidine Tartrate Posterior Segment Drug Delivery System

NCT01080209 is registered in ClinicalTrials.gov with Allergan as lead sponsor.

NCT NCT01080209
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01080209 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety Extension Study to Evaluate the Biodegradation of the Brimonidine Tartrate Posterior Segment Drug Delivery System
Lead sponsor
Allergan
Phase
Phase 2
Overall status
Completed
Start date
February 28, 2010
Completion date
February 28, 2014
Enrollment
215 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

patients who participated in an intravitreal brimo ps dds® study